Cabotegravir
Cabotegravir (CAB) is an integrase strand transfer inhibitor (INSTI) developed for the treatment and prevention of HIV-1 infection.
Cabotegravir (CAB) is an integrase strand transfer inhibitor (INSTI) developed for the treatment and prevention of HIV-1 infection. It exerts its antiviral effect by blocking the integration of viral DNA into the host cell genome, a critical step in the HIV replication cycle. Cabotegravir is distinguished from earlier antiretrovirals by its long-acting pharmacokinetic profile: formulated as a nanosuspension for intramuscular (IM) injection, it achieves sustained plasma concentrations over weeks to months following a single dose, making monthly or bimonthly dosing schedules clinically viable. This property underpins its utility both as a component of long-acting maintenance therapy in people living with HIV-1 and as a long-acting pre-exposure prophylaxis (PrEP) agent.
In the treatment setting, cabotegravir is co-administered with rilpivirine (a non-nucleoside reverse transcriptase inhibitor) as the first complete long-acting injectable regimen approved by the US Food and Drug Administration for virologically suppressed adults with HIV-1. The combination, known as CAB+RPV LA, eliminates the daily oral pill burden characteristic of conventional antiretroviral therapy (ART) and represents a paradigm shift in HIV disease management toward patient-centered, adherence-friendly regimens.
- Formulations at the Nanoscale: Multi-dimensional Electron Diffraction of Long-Acting Injectable, Cabotegravir. PMID 42969722
Where the papers sit
10 papers from the last 6 months study cabotegravir directly
Study type 2 clinical trials · 4 observational · 2 human data · 2 unclassified
Themes one subject · 1 new direction
Those 10 are all about one subject.
-
Long-Acting HIV Treatment
Long-acting cabotegravir is moving from trial-based use toward broader HIV prevention and treatment deployment, especially when daily adherence is difficult. Pharmacokinetic work focuses on injection schedules, the prolonged tail, and pregnancy-to-postpartum dosing, while formulation studies support durable delivery. Real-world and case-series data are defining injection-site and other adverse events, effectiveness, adherence, and virologic failure after switching to cabotegravir plus rilpivirine. Evidence in African adults, pregnant people, and post-marketing populations is expanding, but optimal scheduling and management of the pharmacokinetic tail remain open.
Cabotegravir is examined as a nanoscale crystal material rather than as an antiretroviral intervention
The long-acting injectable cabotegravir formulation studied by the multidimensional electron-diffraction paper is treated as a crystallographic and materials-engineering subject: the work resolves cabotegravir’s structure within the formulation and relates particle shape to crystal structure, growth, and morphology models. This departs from the other papers’ therapeutic, pharmacokinetic, adherence, safety, and implementation roles for cabotegravir by making the drug itself an object of nanoscale structural analysis, with implications for understanding and engineering its sustained-release formulation. 42969722Nov
Papers
The 10 papers from the last 6 months that study cabotegravir directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Long-Acting HIV Treatment (10)
- Formulations at the Nanoscale: Multi-dimensional Electron Diffraction of Long-Acting Injectable, Cabotegravir. Molecular pharmaceutics · 2 Nov 2026 PMID 42969722
- Awareness of and Hypothetical Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Oral Pre-Exposure Prophylaxis Users Who Obtained the Medicine Online in China: Web-Based Cross-Sectional Study. Journal of medical Internet research · 28 Oct 2026 PMID 42950349
- Controlled adherence with long-acting injectable cabotegravir plus rilpivirine: determinants and clinical impact of injection-schedule adherence in the Spanish RELATIVITY cohort. AIDS (London, England) · 23 Oct 2026 PMID 42909514
- Long-Acting HIV Therapy in African Adults with Adherence Challenges. The New England journal of medicine · 14 Oct 2026 PMID 42874104
- Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state. Journal of pharmacokinetics and pharmacodynamics · 23 Sept 2026 PMID 42778687
- Analytical description of adverse events with long-acting injectable cabotegravir and rilpivirine in people living with HIV: a large multicentre prospective observational cohort study (SCOLTA). HIV research & clinical practice · 21 Sept 2026 PMID 42765669
- Risk of Virological Failure After Switch to a Tenofovir-Sparing Dual Therapy in Virologically Suppressed People With HIV and Past HBV Infection. Journal of medical virology · 21 Jul 2026 PMID 42479941
- Real-World Safety and Effectiveness of Cabotegravir in People Living with HIV: Interim Report of a Post-marketing Surveillance in Japan. Advances in therapy · 16 Jul 2026 PMID 42461573
- External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients. CPT: pharmacometrics & systems pharmacology · 22 May 2026 PMID 42170807
- Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series. Antiviral therapy · 13 May 2026 PMID 42125948
By study type
Clinical trials (2)
- Long-Acting HIV Therapy in African Adults with Adherence Challenges. The New England journal of medicine · 14 Oct 2026 PMID 42874104
- Risk of Virological Failure After Switch to a Tenofovir-Sparing Dual Therapy in Virologically Suppressed People With HIV and Past HBV Infection. Journal of medical virology · 21 Jul 2026 PMID 42479941
Observational studies and case reports (4)
- Awareness of and Hypothetical Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Oral Pre-Exposure Prophylaxis Users Who Obtained the Medicine Online in China: Web-Based Cross-Sectional Study. Journal of medical Internet research · 28 Oct 2026 PMID 42950349
- Analytical description of adverse events with long-acting injectable cabotegravir and rilpivirine in people living with HIV: a large multicentre prospective observational cohort study (SCOLTA). HIV research & clinical practice · 21 Sept 2026 PMID 42765669
- External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients. CPT: pharmacometrics & systems pharmacology · 22 May 2026 PMID 42170807
- Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series. Antiviral therapy · 13 May 2026 PMID 42125948
Human data, design not indexed (2)
- Formulations at the Nanoscale: Multi-dimensional Electron Diffraction of Long-Acting Injectable, Cabotegravir. Molecular pharmaceutics · 2 Nov 2026 PMID 42969722
- Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state. Journal of pharmacokinetics and pharmacodynamics · 23 Sept 2026 PMID 42778687
Unclassified: not yet indexed with MeSH (2)
- Controlled adherence with long-acting injectable cabotegravir plus rilpivirine: determinants and clinical impact of injection-schedule adherence in the Spanish RELATIVITY cohort. AIDS (London, England) · 23 Oct 2026 PMID 42909514
- Real-World Safety and Effectiveness of Cabotegravir in People Living with HIV: Interim Report of a Post-marketing Surveillance in Japan. Advances in therapy · 16 Jul 2026 PMID 42461573
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-07-29 by GPT. Drafted by language models from published abstracts; not medical advice.